Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.65 |
| ▸ | PTPRA | P18433 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ACLY | P53396 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PTPRF | P10586 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979550 | 0.89 | NPSR1 (0.65) | PTPN1PTPRANPSR1KMT2AKDM4E | |
| SCHEMBL6534391 | 0.82 | PTPN1 (0.75) | PTPN1PTPRANPSR1KMT2AKDM4E | |
| SCHEMBL6311435 | 0.79 | PTPN1 (1.00) | PTPN1PTPRANPSR1KMT2AKDM4E | |
| SCHEMBL3076668 | 0.79 | PTPN1 (0.75) | PTPN1PTPRANPSR1KMT2AKDM4E | |
| SCHEMBL17226318 | 0.79 | PTPN1 (0.70) | PTPN1PTPRANPSR1KMT2AKDM4E | |
| SCHEMBL2157462 | 0.78 | PTPN1 (0.62) | PTPN1PTPRANPSR1KMT2AKDM4E | |
| SCHEMBL1752172 | 0.76 | PTPN1 (0.46) | PTPN1PTPRANPSR1KMT2AKDM4E | |
| SCHEMBL3607693 | 0.75 | LCK (0.42) | PTPN1PTPRF | |
| SCHEMBL668558 | 0.75 | RAF1 (0.49) | NPSR1KMT2A | |
| SCHEMBL2157766 | 0.73 | MAPT (0.67) | PTPN1PTPRANPSR1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448545-B1 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7166639-B2 | NF-κB inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1448545-A4 | NF-KB INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040192943-A1 | Nf-kappab inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | disclosed |
| EP-1448545-A1 | NF-KB INHIBITORS | SmithKline Beecham Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003029242-A1 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192943-A1 | Nf-kappab inhibitors | NFKBIA, IKBKB, IKBKG | PTPN1 1424/4885PTPRA 676/4885NPSR1 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.